Polina Savina

Dr. Polina Savina

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2022 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
DAD. Kh. Ainetdinova
D. Kh. Ainetdinova
KEKogan Evgenija
Kogan Evgenija
YLYulia Lutokhina
Yulia Lutokhina
VNV. M. Novosadov
V. M. Novosadov
АЗА. Ю. Зайцев
А. Ю. Зайцев
The possibility of heart inflammation (both myocardial and endocardial) months after a coronavirus disease 2019 (COVID-19) has not been practically studied, especially since approaches to the treatment of myocarditis in combination with various endocarditis forms have not been developed.Aim. To study the prevalence and mechanisms of SARS-CoV-2-associated endocardial injury in patients with morphologically verified post-COVID-19 myocarditis, as well as to develop approaches to comprehensive therapy.Material and methods. The study included 18 patients with severe morphologically verified post-COVID-19 myocarditis (men, 9; 51,1±9,4 years; 35 to 66 years). Patients with prior verified myocarditis/myocardial infarction, rheumatic heart disease, and systemic immune diseases were excluded. The average time after COVID-19 was 6,5 [3.5; 10] months The diagnosis of myocarditis was confirmed by endomyocardial biopsy (including immunohistochemical examination with antibodies to CD3, CD20, CD45, CD68, and to SARS-CoV-2 antigens; polymerase chain reaction for SARS-CoV-2 RNA, DNA of cardiotropic viruses). The blood level of anticardiac antibodies was determined by indirect immunofluorescence. In addition, echocardiography, magnetic resonance imaging (n=8), cardiac multislice tomography (n=1), and coronary angiography (n=14) were performed.Results. Biopsy revealed active (n=12) and borderline (n=3) lymphocytic myocarditis, eosinophilic (n=2) and giant cell (n=1) myocarditis. In 4 patients, nonbacterial thrombotic endocarditis (NBTE) with parietal and intravascular thrombosis was diagnosed, and in one patient — infective endocarditis (IE) of the bicuspid aortic valve. Myocardial persistence of SARS-CoV-2 was detected in 72% of cases (in 3 patients — with NBTE; in 1 — with IE; in 9 — without endocarditis). Titers of anticardiac antibodies increased by 3-4 times in 94% of patients. Patients with endocarditis were characterized by larger heart chambers, lower ejection fraction (27,5±6,6 vs 36,0±13,4%), more severe pulmonary hypertension, and valvular regurgitation. Intraventricular thrombosis according to echocardiography/magnetic resonance imaging and cardiac embolism was not observed. Treatment in all patients included methylprednisolone at an average dose of 24 mg a day. In 10 patients, the result was monitored for at least 3 months as follows: the ejection fraction was 46,0±12,7% and 44,3±7,3% in patients with and without endocarditis, respectively.Conclusion. Endocarditis in patients with post-COVID-19 myocarditis was detected in 28% (1 patient — IE; 4 — NBTE). The key mechanisms of post-COVID-19 myocarditis and NBTE are long-term (up to 18 months) myocardial persistence of SARS-Cov-2 and the development of an autoimmune reaction. Endocarditis was diagnosed in more severe patients, including those with giant cell and eosinophilic myocarditis. The effectiveness of steroid therapy in combination with anticoagulants in patients with NBTE requires further study. In case of IE, steroids can also be used in the treatment of myocarditis (in combination with antibiotics and immunoglobulin).

8 October 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
PSPolina Savina
Polina Savina
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
DAD. Kh. Ainetdinova
D. Kh. Ainetdinova
ASA. V. Sedov
A. V. Sedov
Ekaterina PavlenkoEkaterina Pavlenko
Ekaterina Pavlenko
ЮЛЮ. А. Лутохина
Ю. А. Лутохина
Aim. To study the mechanisms and clinical variants of subacute and chronic myocarditis after SARS-CoV-2 infection using morphological and virological studies and to develop approaches to its treatment.Material and methods. The study included 89 patients with documented coronavirus disease 2019 (COVID-19). The diagnosis of post-COVID myocarditis was established based on myocardial biopsy and/or cardiac magnetic resonance imaging (MRI) data in combination with anamnesis, increased titers of anticardiac antibodies, and other criteria. The average time of presentation after infection was 8,0 [4; 17,5] months, while the average follow-up period was 7,0 [6,0; 13,5] months. Electrocardiography, Holter monitoring, echocardiography, cardiac MRI (n=60), determination of anticardiac antibody levels, myocardial biopsy (n=38), and autopsy (n=1) were performed.Results. All patients showed an association between the onset or exacerbation of cardiac symptoms and COVID-19. The clinical variants of post-COVID myocarditis were identified: arrhythmic (n=24) with newly developed arrhythmias with normal myocardial contractility; decompensated (n=65) with newly diagnosed heart failure, including a variant developed with primary (genetic) cardiomyopathies and amyloidosis (n=10). The profile of arrhythmias in the arrhythmic variant varied from potentially life-threatening rhythm and conduction disorders (sustained ventricular tachycardia, grade II-III atrioventricular block) to infrequent supraventricular premature beats. In the decompensated variant, lymphocytic myocarditis was most often morphologically detected, while eosinophilic and giant cell myocarditis, associated with a worse prognosis, were rarer. Simultaneous development of nonbacterial thrombotic endocarditis, infective endocarditis with the development of valvular heart defects was noted. In 10 cases, myocarditis was combined with primary cardiomyopathies, AL amyloidosis. Treatment included the administration of antiarrhythmic, cardiotropic, immunosuppressive therapy (glucocorticoids 16-32 mg/day in 68,5% of patients, hydroxychloroquine 200-400 mg/day in 33,7%). In the arrhythmic type, complete arrhythmia suppression was achieved in 25% of cases, while partial in 58,3%. In one case, a pacemaker was implanted. In patients with a decompensated myocarditis, corticosteroids were effective regardless of the viral genome/proteins in the myocardium.Conclusion. COVID-19 can induce subacute and chronic myocarditis with the development of isolated arrhythmias or severe heart failure.

12 August 2024 in Genes
Verified
Journal Article
Open access
PDF file
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
YLYulia Lutokhina
Yulia Lutokhina
KEKogan Evgenija
Kogan Evgenija
PSPolina Savina
Polina Savina
SASvetlana Alexandrova
Svetlana Alexandrova
EZElena Zaklyazminskaya
Elena Zaklyazminskaya
The aim of this study was to evaluate the clinical course and outcomes of post-COVID myocarditis in patients with cardiomyopathies (CMP). This case series includes 10 patients with different CMPs who had COVID-19 (seven men; 48.4 ± 11.4 yr.): left ventricular non-compaction (n = 2), arrhythmogenic right ventricular CMP in combination with a heterozygous form of hemochromatosis (n = 1, HFE), restrictive CMP (n = 1, MyBPC3), laminopathy (n = 1, LMNA), dilated cardiomyopathy (n = 1, MYH7 + MyBPC3), Danon’s disease (n = 1, LAMP2) and AL cardiac amyloidosis (n = 3). Myocardial morphological examination with immunohistochemical staining and PCR for SARS-CoV-2 and cardiotropic viruses was performed in six patients, while cardiac MRI and anti-cardiac antibody titres were evaluated in all patients. Post-COVID lymphocytic myocarditis was confirmed morphologically in six patients (with LVNC, RCM, ARCV, Danon’s disease, and AL amyloidosis). Spike and nucleocapsid coronavirus proteins were detected in cell infiltrates, endothelium and cardiomyocytes in all biopsies; SARS-CoV-2 RNA was found in five out of six. In four patients, the diagnosis of myocarditis was based on MRI, high titres of anti-cardiac antibodies and clinical data. The mean time from COVID-19 to the diagnosis of myocarditis was 7 (5; 10.5) months. Myocarditis manifested with the onset/increase of arrhythmias and heart failure. Immunosuppressive therapy with corticosteroids was administered to six patients and led to an increase in ejection fraction and improvement of heart failure symptoms in five of them. CMPs are a favourable background for the development of post-COVID myocarditis. The onset or deterioration of heart failure and/or arrhythmias in patients with CMPs after COVID-19 requires the exclusion of myocarditis and, if present, the administration of immunosuppressive therapy.

12 May 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
YLYulia Lutokhina
Yulia Lutokhina
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
PSPolina Savina
Polina Savina
EZElena Zaklyazminskaya
Elena Zaklyazminskaya
A 64-year-old female with a family history of hereditary hemorrhagic telangiectasia (HHT) was hospitalized due to complaints of dyspnea during light physical exertion and leg edema. HHT was diagnosed at 20 y.o., recurrent nasal bleeding started at age 52, bleedings severity was aggravated by not completely compensated hypertension. At the age of 60, after a massive hemorrhage, she noted the onset of dyspnea, edema, ascites. Diuretics and iron preparations improved her well-being, but from that period onward her heart failure worsened after each massive blood loss. The last major bleeding was before the present hospitalization (Hgb 67 g/l), after which heart failure symptoms significantly deteriorated. Echocardiography showed preserved left ventricular ejection fraction, but revealed high pulmonary hypertension (systolic pulmonary artery pressure 69 mmHg). Chest computed tomography (CT) with contrast showed no evidence of pulmonary embolism, but interstitial lung lesions were detected. Pulse therapy with glucocorticosteroids did not result in positive dynamics at the control CT scan, which allowed to reject a separate interstitial lung disease. As a result of cardiotropic and diuretic therapy, as well as correction of anemia, the patient's condition improved. Macitentan was administered, but the patient refused from it because one of possible side effects was anemia. A year later the patient diedfrom acute progression of pulmonary hypertension. According to the literature, pulmonary hypertension in HHT can have a significant impact on the prognosis and requires timely diagnosis and treatment. Interstitial lung lesions are a manifestation of the underlying disease and does not require special treatment.

8 April 2024 in Russian Journal of Cardiology and Cardiovascular Surgery
Verified
Journal Article
Closed access
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
DAD.KH. Ainetdinova
D.KH. Ainetdinova
PSPolina Savina
Polina Savina
YLYulia Lutokhina
Yulia Lutokhina
Ekaterina PavlenkoEkaterina Pavlenko
Ekaterina Pavlenko
KEKogan Evgenija
Kogan Evgenija
OBJECTIVE To analyze cases of verified myo-/pericarditis after injection of Russian vaccines against SARS-CoV-2 infection considering previous COVID-19 disease. MATERIAL AND METHODS The register of patients with post-Covid myo-/pericarditis (September 2020 — June 2022) includes 60 patients (27 women and 33 men), their average age is 50.7±13.8 years. Diagnostic criteria were previous novel coronavirus infection and/or vaccination against COVID-19, arrhythmias/heart failure after COVID-19 and/or vaccination, 2 Lake Louise MR criteria for myocarditis (2018) (n=44) and /or Dallas criteria based on endomyocardial biopsy (EMB) (n=16). In 12 patients (6 men, mean age 47.3±13.1 years), myocarditis was induced by Gam-COVID-Vac or CoviVac vaccines (3 ones without previous COVID-19 and 9 patients with previous infection). We analyzed the myocardium using PCR for DNA of cardiotropic viruses and SARS-CoV-2 RNA. Anticardiac antibodies were estimated by indirect immunofluorescence analysis. Coronary angiography (n=25) and cardiac CT (n=4) were performed. RESULTS In 3 patients without previous COVID-19, subacute/chronic post-vaccination myocarditis developed from several days to 2—3 months after administration of the 2nd dose and proceeded in a decompensated form (LV ejection fraction 25—35%). In 2 cases, steroids were required. In 9 people with previous COVID-19, the period until myocarditis after disease averaged 7.5 [4.5; 8.75] months (range 4—3). There were 1—60 days after vaccination. Myocarditis occurred in arrhythmic (n=5) and decompensated (n=4) forms. EMB revealed active lymphocytic myocarditis with persistence of SARS-CoV-2 in the myocardium in 2 patients. All 12 patients had 3—4 times increased titers of anticardiac antibodies. Six patients were treated with methylprednisolone 16—32 mg/day, other ones — hydroxychloroquine 200 mg/day. One patient with decompensated variant died. CONCLUSION Russian COVID-19 vaccines in patients without previous myocarditis or COVID-19 can lead to post-vaccination subacute/chronic myo-/pericarditis. Previous COVID-19 and allergic diseases increase this risk. Clinical picture, course and complications of post-Covid and post-vaccination myocarditis are very similar. Corticosteroids are quite effective for all forms of post-vaccination myo-/pericarditis.

17 October 2023 in Journal of Arrhythmology
Verified
Journal Article
Open access
PDF file
PSPolina Savina
Polina Savina
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
DAD. Kh. Ainetdinova
D. Kh. Ainetdinova
ASA. V. Sedov
A. V. Sedov
INI. V. Novikova
I. V. Novikova
SASvetlana Alexandrova
Svetlana Alexandrova
Aim. To study the spectrum of rhythm and conduction disorders in patients with arrhythmic variant of postcovid myocarditis and determine the treatment approaches.Methods. The study included 23 patients with post-COVID-19 по абстракту разное написание. Post-COVID arrhythmias who had at least two of the three Lake-Louise criteria for myocarditis on magnetic resonance imaging of the heart and/or elevated anticardiac antibody (ACA) titers. The period of occurrence of post-COVID arrhythmias was 4.0 [2.0; 8.0] months, from 2 to 34 months. Echocardiography, Holter monitoring, and ACA study were performed. Cardiac magnetic resonance imaging was performed in 70% of patients (n=16). Coronary artery disease was excluded in 9 patients with risk factors.Results. In all patients’ arrhythmias were associated with COVID-19. Rhythm and conduction disturbances occurred within 2 to 34 months after infection. Echocardiography revealed no left ventricle systolic dysfunction. In all patients, an increase in ACA by 3 or more times was noted, in 65.2% (n=15) a specific antinuclear factor (ANF) was detected, reflecting the high immunological activity of myocarditis. Ventricular arrhythmias in most cases were represented by frequent ventricular extrasystole. Among supraventricular arrhythmias, frequent extrasystoles, non-sustained tachycardia, paroxysmal form of atrial fibrillation were detected. In one case, a transient atrioventricular block II-III degree developed. Treatment approaches included antiarrhythmic and immunosuppressive therapy. All patients underwent Holter monitoring, which showed regression of arrhythmias. Patients with high immunological activity of myocarditis underwent immunosuppressive therapy with methylprednisolone 8-16 mg/day (n=13), with moderate - mild immune-suppressive therapy with hydroxychloroquine 200 mg/day (n=10). When controlling the ACA titers, their decrease was noted. The decrease in the specific ANF titer was close to statistically significant (p=0.057). Interventional treatment of arrhythmias was performed in three patients.Conclusions. Arrhythmias that first developed after COVID-19 require the exclusion of subacute/chronic myocarditis that develops 2-8 months after COVID-19. The spectrum of arrhythmias in patients with post-COVID myocarditis is mostly represented by frequent symptomatic extrasystoles. Basic therapy of the arrhythmic variant of post-COVID myocarditis with methylprednisolone and/or hydroxychloroquine makes it possible to increase the effectiveness of antiarrhythmic drugs with the opportunity of their complete withdrawal in some patients.